BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

792 related articles for article (PubMed ID: 17996590)

  • 1. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
    Kyle RA; Rajkumar SV
    Hematol Oncol Clin North Am; 2007 Dec; 21(6):1093-113, ix. PubMed ID: 17996590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monoclonal gammopathies of undetermined significance.
    Kyle RA; Rajkumar SV
    Best Pract Res Clin Haematol; 2005; 18(4):689-707. PubMed ID: 16026745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Monoclonal gammopathy of undetermined significance].
    Chaïbi P; Merlin L; Thomas C; Piette F
    Ann Med Interne (Paris); 2002 Nov; 153(7):459-66. PubMed ID: 12598832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
    Kyle RA; San-Miguel JF; Mateos MV; Rajkumar SV
    Hematol Oncol Clin North Am; 2014 Oct; 28(5):775-90. PubMed ID: 25212882
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Venous thromboembolism in patients with monoclonal gammopathy of undetermined significance.
    Muslimani AA; Spiro TP; Chaudhry AA; Taylor HC; Jaiyesimi I; Daw HA
    Clin Adv Hematol Oncol; 2009 Dec; 7(12):827-32. PubMed ID: 20332755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Monoclonal gammopathy of undetermined significance (MGUS) in Mexican mestizos: one institution's experience].
    Ruiz-Delgado GJ; Gómez Rangel JD
    Gac Med Mex; 2004; 140(4):375-9. PubMed ID: 15456147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monoclonal gammopathy of undetermined significance and smouldering multiple myeloma: emphasis on risk factors for progression.
    Kyle RA; Rajkumar SV
    Br J Haematol; 2007 Dec; 139(5):730-43. PubMed ID: 18021088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Benign monoclonal gammopathy].
    Shirota T; Kondo M; Uchida H; Ito H
    Nihon Rinsho; 1995 Mar; 53(3):720-4. PubMed ID: 7699912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term follow-up of patients with monoclonal gammopathy of undetermined significance after kidney transplantation.
    Naina HV; Harris S; Dispenzieri A; Cosio FG; Habermann TM; Stegall MD; Dean PG; Prieto M; Kyle RA; Rajkumar SV; Leung N
    Am J Nephrol; 2012; 35(4):365-71. PubMed ID: 22473253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence and evolution of monoclonal gammopathy of undetermined significance (MGUS) in Greece.
    Anagnostopoulos A; Evangelopoulou A; Sotou D; Gika D; Mitsibounas D; Dimopoulos MA
    Ann Hematol; 2002 Jul; 81(7):357-61. PubMed ID: 12185503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Should bone marrow examination be routinely performed for the diagnosis of monoclonal gammopathy of undetermined significance?
    Elis A; Radnay J; Shapiro H; Itzhaky D; Manor Y; Lishner M
    Isr Med Assoc J; 2006 Dec; 8(12):840-2. PubMed ID: 17214099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Monoclonal gammopathy of undetermined significance--potential risk factor of multiple myeloma].
    Stelmach-Gołdyś A; Czarkowska-Paczek B
    Przegl Lek; 2012; 69(5):194-6. PubMed ID: 23050415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
    Rajkumar SV; Lacy MQ; Kyle RA
    Blood Rev; 2007 Sep; 21(5):255-65. PubMed ID: 17367905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma.
    Ribatti D; Vacca A; Nico B; Quondamatteo F; Ria R; Minischetti M; Marzullo A; Herken R; Roncali L; Dammacco F
    Br J Cancer; 1999 Feb; 79(3-4):451-5. PubMed ID: 10027312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The incidental monoclonal protein: current approach to management of monoclonal gammopathy of undetermined significance (MGUS).
    Madan S; Greipp PR
    Blood Rev; 2009 Nov; 23(6):257-65. PubMed ID: 19699016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A long-term study of prognosis in monoclonal gammopathy of undetermined significance.
    Kyle RA; Therneau TM; Rajkumar SV; Offord JR; Larson DR; Plevak MF; Melton LJ
    N Engl J Med; 2002 Feb; 346(8):564-9. PubMed ID: 11856795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monoclonal gammopathy of undetermined significance.
    Kyle RA; Rajkumar SV
    Br J Haematol; 2006 Sep; 134(6):573-89. PubMed ID: 16938117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone-marrow immunophenotypic analysis allows the identification of high risk of progression and immune condition-related monoclonal gammopathy of undetermined significance.
    Jerez A; Ortuño FJ; Osma Mdel M; Español I; González AD; Roldán V; de Arriba F; Vicente V
    Ann Med; 2009; 41(7):547-58. PubMed ID: 19634064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The clinical significance of M proteins].
    Sasaki R
    Rinsho Byori; 2001 Jul; 49(7):678-81. PubMed ID: 11519130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Multiple myeloma after monoclonal gammopathy of uncertain significance. Study of 10 patients].
    Salgado C; Bladé J; López-Guillermo A; Cervantes F; Montserrat E; Rozman C
    Sangre (Barc); 1993 Oct; 38(5):371-4. PubMed ID: 8140498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.